Shockwave Medical, Inc. (NASDAQ:SWAV) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET

Company Participants

Debbie Kaster - Vice President, Investor Relations

Doug Godshall - President and Chief Executive Officer

Isaac Zacharias - President and Chief Commercial Officer

Trinh Phung - Vice President, Finance

Conference Call Participants

Adam Maeder - Piper Sandler

Bill Plovanic - Canaccord Genuity

Travis Steed - Bank of America

Larry Biegelsen - Wells Fargo

Michael Polark - Wolfe Research

Cecilia Furlong - Morgan Stanley

Imron Zafar - Deutsche Bank

Mike Matson - Needham

Operator

Good afternoon. And welcome to Shockwave’s First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Debbie Kaster, Vice President of Investor Relations of Shockwave for a few introductory comments. Please go ahead.

Debbie Kaster

Thank you all for participating in today’s call. Joining me today from Shockwave Medical are Doug Godshall, President and Chief Executive Officer; Isaac Zacharias, President and Chief Commercial Officer; and Trinh Phung, Vice President of Finance, who is standing in for Dan Puckett, while he is out of the country on a much deserved family vacation. Earlier today, Shockwave released financial results for the quarter ended March 31, 2023. A copy of the press release is available on Shockwave’s website.

Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call other than statements of historical fact are forward-looking statements. All forward-looking statements, including, without limitation, statements relating to our sales and operating trends, business and hiring prospects, financial and revenue expectations, reimbursement proposal, future product development and approval, and integration of Neovasc and its technologies into our business are based upon our current estimates and various assumptions.

These statements involve material risks and uncertainties, including the impact of macroeconomic conditions and global events such as the COVID-19 pandemic that could cause actual results or events to material differ -- materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.